This invention relates to pharmaceutical compositions and methods for treating alopecia and promoting hair growth using n-oxides of heterocyclic esters, amides, thioesters, or ketones.
|
1. A method for treating alopecia or promoting hair growth in an animal in need thereof, which comprises administering to said animal an effective amount of a non-immunosuppressive nitrogen-containing heterocyclic compound which has an n-linked ketone, diketo, or thioketo substituent, and which is additionally substituted with an n-oxide of an ester, amide, thioester, or ketone substituent attached to the heterocyclic ring, wherein said compound has an affinity for an fkbp-type immunophilin.
3. A method for treating alopecia or promoting hair growth in an animal in need thereof, which comprises administering to said animal an effective amount of a compound of formula I ##STR14##
or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein: A and b are taken together, with the nitrogen and carbon atoms to which they are respectively attached, to form a 5-7 membered saturated or unsaturated heterocyclic ring which has any combination of CH, CH2, O, S, SO, SO2, n, NH and NR1 ; W is O, S, CH2, or H2 ; R is C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C3 -C8 cycloalkyl, C5 -C7 cycloalkenyl, or ar1, which is optionally substituted with one or more substituent(s) independently selected from the group consisting of C1 -C4 alkyl, C2 -C4 alkenyl, hydroxy, C3 -C8 cycloalkyl, C5 -C7 cycloalkenyl, and ar2 ; ar1 and ar2 are independently selected from the group consisting of 1-napthyl, 2-napthyl, 1-indolyl, 2-indolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, and phenyl, having one or more substituent(s) independently selected from the group consisting of hydrogen, halo, hydroxy, nitro, trifluoromethyl, C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C2 -C4 alkenyloxy, phenoxy, benzyloxy, and amino; X is O, NH, NR1, S, CH, CR1, or CR1 R3 ; Y is a direct bond, C1 -C6 straight or branched chain alkyl, or C2 -C6 straight or branched chain alkenyl; wherein said alkyl or alkenyl is optionally substituted with one or more substituent(s) independently selected from the group consisting of C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C3 -C8 cycloalkyl, C5 -C7 cycloalkenyl, hydroxy, carbonyl oxygen, and ar; wherein said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or ar is optionally substituted with C1 -C4 alkyl, C2 -C4 alkenyl, hydroxy, or carbonyl oxygen; wherein any carbon atom of said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or ar is optionally replaced with O, NH, NR2, S, SO, or SO2 ; R2 is selected from the group consisting of hydrogen, C1 -C4 straight or branched chain alkyl, C3 -C4 straight or branched chain alkenyl or alkynyl, and C1 -C4 bridging alkyl wherein a bridge is formed between the nitrogen and a carbon atom of said alkyl or alkenyl chain having said heteroatom to form a ring, wherein said ring is optionally fused to an ar group; Z is an aromatic amine or a tertiary amine oxidized to a corresponding n-oxide; said aromatic amine is pyridyl, pyrimidyl, quinolinyl, or isoquinolinyl, which is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of halo, hydroxy, nitro, trifluoromethyl, C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C1 -C4 alkoxy, C2 -C4 alkenyloxy, phenoxy, benzyloxy, and amino; said tertiary amine is NR4 R5 R6, wherein R4, R5, and R6 are independently selected from the group consisting of C1 -C6 straight or branched chain alkyl and C2 -C6 straight or branched chain alkenyl; wherein said alkyl or alkenyl is optionally substituted with one or more substituent(s) independently selected from the group consisting of C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C3 -C8 cycloalkyl, C5 -C7 cycloalkenyl, hydroxy, carbonyl oxygen, and ar; wherein said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or ar is optionally substituted with C1 -C4 alkyl, C2 -C4 alkenyl, hydroxy, or carbonyl oxygen; wherein any carbon atom of said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or ar is optionally replaced with O, NH, NR1, S, SO, or SO2 ; ar is selected from the group consisting of pyrrolidinyl, pyridyl, pyrimidyl, pyrazyl, pyridazyl, quinolinyl, and isoquinolinyl; and R1 and R3 are independently hydrogen, C1 -C4 straight or branched chain alkyl, C3 -C4 straight or branched chain alkenyl or alkynyl, or Y--Z. 8. A method for treating alopecia or promoting hair growth in an animal in need thereof, which comprises administering to said animal an effective amount of a compound of formula v ##STR18##
or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein: v is C, n, or S; A and b, taken together with v and the carbon atom to which they are respectively attached, form a 5-7 membered saturated or unsaturated heterocyclic ring which has one or more heteroatom(s) selected from the group consisting of O, S, SO, SO2, n, NH, and NR7 ; R, is either C1 -C9 straight or branched chain alkyl, C2 -C9 straight or branched chain alkenyl, C3 -C9 cycloalkyl, C5 -C7 cycloalkenyl, or ar3, wherein R7 is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of halo, haloalkyl, carbonyl, carboxy, hydroxy, nitro, trifluoromethyl, C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C1 -C4 alkoxy, C2 -C4 alkenyloxy, phenoxy, benzyloxy, thioalkyl, alkylthio, sulfhydryl, amino, alkylamino, aminoalkyl, aminocarboxyl, and ar4 ; ar3 and ar4 are independently an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring; wherein the individual ring size is 5-8 members; wherein said heterocyclic ring has 1-6 heteroatom(s) independently selected from the group consisting of O, n, and S; W is O, S, CH2, or H2 ; R is C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C3 -C8 cycloalkyl, C5 -C7 cycloalkenyl, or ar1, which is optionally substituted with one or more substituent(s) independently selected from the group consisting of C1 -C4 alkyl, C2 -C4 alkenyl, hydroxy, C3 -C8 cycloalkyl, C5 -C7 cycloalkenyl, and ar2 ; ar1 and ar2 are independently selected from the group consisting of 1-napthyl, 2-napthyl, 1-indolyl, 2-indolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, and phenyl, having one or more substituent(s) independently selected from the group consisting of hydrogen, halo, hydroxy, nitro, trifluoromethyl, C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C2 -C4 alkenyloxy, phenoxy, benzyloxy, and amino; X is O, NH, NR1, S, CH, CR1, or CR1 R3 ; Y is a direct bond, C1 -C6 straight or branched chain alkyl, or C2 -C6 straight or branched chain alkenyl; wherein said alkyl or alkenyl is optionally substituted with one or more substituent(s) independently selected from the group consisting of C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C3 -C8 cycloalkyl, C5 -C7 cycloalkenyl, hydroxy, carbonyl oxygen, and ar; wherein said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or ar is optionally substituted with C1 -C4 alkyl, C2 -C4 alkenyl, hydroxy, or carbonyl oxygen; wherein any carbon atom of said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or ar is optionally replaced with O, NH, NR2, S, SO, or SO2 ; R2 is selected from the group consisting of hydrogen, C1 -C4 straight or branched chain alkyl, C3 -C4 straight or branched chain alkenyl or alkynyl, and C1 -C4 bridging alkyl wherein a bridge is formed between the nitrogen and a carbon atom of said alkyl or alkenyl chain having said heteroatom to form a ring, wherein said ring is optionally fused to an ar group; Z is an aromatic amine or a tertiary amine oxidized to a corresponding n-oxide; said aromatic amine is pyridyl, pyrimidyl, quinolinyl, or isoquinolinyl, which is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of halo, hydroxy, nitro, trifluoromethyl, C1 -C6 straight or branched chain alkyl, C2 -hd 4 straight or branched chain alkenyl, C1 -C4 alkoxy, C2 -C4 alkenyloxy, phenoxy, benzyloxy, and amino; said tertiary amine is NR4 R5 R6, wherein R4, R5, and R6 are independently selected from the group consisting of C1 -C6 straight or branched chain alkyl and C2 -C6 straight or branched chain alkenyl; wherein said alkyl or alkenyl is optionally substituted with one or more substituent(s) independently selected from the group consisting of C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C3 -C8 cycloalkyl, C5 -C7 cycloalkenyl, hydroxy, carbonyl oxygen, and ar; wherein said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or ar is optionally substituted with C1 -C4 alkyl, C2 -C4 alkenyl, hydroxy, or carbonyl oxygen; wherein any carbon atom of said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or ar is optionally replaced with O, NH, NR1, S, SO, or SO2 ; ar is selected from the group consisting of pyrrolidinyl, pyridyl, pyrimidyl, pyrazyl, pyridazyl, quinolinyl, and isoquinolinyl; and R1 and R3 are independently hydrogen, C1 -C4 straight or branched chain alkyl, C3 -C4 straight or branched chain alkenyl or alkynyl, or Y--Z. 4. The method of
or a pharamaceutically acceptable salt, ester, or solvate thereof, wherein: E, F, G and J are independently CH2, O, S, SO, SO2, NH or Nr1 ; W is O, S, CH2, or H2 ; R is C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C3 -C8 cycloalkyl, C5 -C7 cycloalkenyl, and ar1 ; which is optionally substituted with one or more substituent(s) independently selected from the group consisting of C1 -C4 alkyl, C2 -C4 alkenyl, hydroxy, C3 -C8 cycloalkyl, C5 -C7 cycloalkenyl, and ar1 ; ar1 is selected from the group consisting of 1-naphthyl, 2-napthyl, 1-indolyl, 2-indolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl and phenyl, having one or more substituent(s) independently selected from the group consisting of hydrogen, halo, hydroxy, nitro, trifluoromethyl, C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C2 -C4 alkenyloxy, phenoxy, benzyloxy, and amino; X is O, NH, NR1, S, CH, CR1, or CR1 R3 ; Y is a direct bond, C1 -C6 straight or branched chain alkyl, or C2 -C6 straight or branched chain alkenyl; wherein said alkyl or alkenyl is optionally substituted with one or more substituent(s) independently selected from the group consisting of C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C3 -C8 cycloalkyl, C5 -C7 cycloalkenyl, hydroxy, carbonyl oxygen, and ar; wherein said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or ar is optionally substituted with C1 -C4 alkyl, C2 -C4 alkenyl, hydroxy, or carbonyl oxygen; wherein any carbon atom of said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or ar is optionally replaced with O, NH, NR2, S, SO, or SO2 ; R2 is selected from the group consisting of hydrogen, C1 -C4 straight or branched chain alkyl, C3 -C4 straight or branched chain alkenyl or alkynyl, and C1 -C4 bridging alkyl wherein a bridge is formed between the nitrogen and a carbon atom of said alkyl or alkenyl chain having said heteroatom to form a ring, wherein said ring is optionally fused to an ar group; Z is an aromatic amine or a tertiary amine oxidized to a corresponding n-oxide; said aromatic amine is pyridyl, pyrimidyl, quinolinyl, or isoquinolinyl, which is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of halo, hydroxy, nitro, trifluoromethyl, C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C1 -C4 alkoxy, C2 -C4 alkenyloxy, phenoxy, benzyloxy, and amino; said tertiary amine is NR4 R5 R6, wherein R4, R5, and R6 are independently selected from the group consisting of C1 -C6 straight or branched chain alkyl and C2 -C6 straight or branched chain alkenyl; wherein said alkyl or alkenyl is optionally substituted with one or more substituent(s) independently selected from the group consisting of C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C3 -C8 cycloalkyl, C5 -C7 cycloalkenyl, hydroxy, carbonyl oxygen, and ar; wherein said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or ar is optionally substituted with C1 -C4 alkyl, C2 -C4 alkenyl, hydroxy, or carbonyl oxygen; wherein any carbon atom of said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or ar is optionally replaced with O, NH, NR1, S, SO, or SO2 ; ar is selected from the group consisting of pyrrolidinyl, pyridyl, pyrimidyl, pyrazyl, pyridazyl, quinolinyl, and isoquinolinyl; and R1 and R3 are independently hydrogen, C1 -C4 straight or branched chain alkyl, C3 -C4 straight or branched chain alkenyl or alkynyl, or Y--Z. 5. The method of
or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein: E, F, and G are independently CH2, O, S, SO, SO2, NH or NR1 ; W is O, S, CH2, or H2 ; R is C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C3 -C8 cycloalkyl, C5 -C7 cycloalkenyl, or ar1, which is optionally substituted with one or more substituent(s) independently selected from the group consisting of C1 -C4 alkyl, C2 -C4 alkenyl, hydroxy, C3 -C8 cycloalkyl, C5 -C7 cycloalkenyl, and ar1 ; ar1 is selected from the group consisting of 1-napthyl, 2-napthyl, 1-indolyl, 2-indolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl and phenyl, having one or more substituent(s) independently selected from the group consisting of hydrogen, halo, hydroxy, nitro, trifluoromethyl, C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C2 -C4 alkenyloxy, phenoxy, benzyloxy, and amino; X is O, NH, NR1, S, CH, CR1, or CR1 R3 ; Y is a direct bond, C1 -C6 straight or branched chain alkyl, or C2 -C6 straight or branched chain alkenyl; wherein said alkyl or alkenyl is optionally substituted with one or more substituent(s) independently selected from the group consisting of C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C3 -C8 cycloalkyl, C5 -C7 cycloalkenyl, hydroxy, carbonyl oxygen, and ar; wherein said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or ar is optionally substituted with C1 -C4 alkyl, C2 -C4 alkenyl, hydroxy, or carbonyl oxygen; wherein any carbon atom of said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or ar is optionally replaced with O, NH, NR2, S, SO, or SO2 ; R2 is selected from the group consisting of hydrogen, C1 -C4 straight or branched chain alkyl, C3 -C4 straight or branched chain alkenyl or alkynyl, and C1 -C4 bridging alkyl wherein a bridge is formed between the nitrogen and a carbon atom of said alkyl or alkenyl chain having said heteroatom to form a ring, wherein said ring is optionally fused to an ar group; Z is an aromatic amine or a tertiary amine oxidized to a corresponding n-oxide; said aromatic amine is pyridyl, pyrimidyl, quinolinyl, or isoquinolinyl, which is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of halo, hydroxy, nitro, trifluoromethyl, C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C1 -C4 alkoxy, C2 -C4 alkenyloxy, phenoxy, benzyloxy, and amino; said tertiary amine is NR4 R5 R6, wherein R4, R5, and R6 are independently selected from the group consisting of C1 -C6 straight or branched chain alkyl and C2 -C6 straight or branched chain alkenyl; wherein said alkyl or alkenyl is optionally substituted with one or more substituent(s) independently selected from the group consisting of C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C3 -C8 cycloalkyl, C5 -C7 cycloalkenyl, hydroxy, carbonyl oxygen, and ar; wherein said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or ar is optionally substituted with C1 -C4 alkyl, C2 -C4 alkenyl, hydroxy, or carbonyl oxygen; wherein any carbon atom of said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or ar is optionally replaced with O, NH, NR1, S, SO, or SO2 ; ar is selected from the group consisting of pyrrolidinyl, pyridyl, pyrimidyl, pyrazyl, pyridazyl, quinolinyl, and isoquinolinyl; and R1 and R3 are independently hydrogen, C1 -C4 straight or branched chain alkyl, C3 -C4 straight or branched chain alkenyl or alkynyl, or Y--Z. 6. The method of
or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein: n is 1, 2 or 3 forming a 5-7 member heterocyclic ring; W is O, S, CH2, or H2 ; R is C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C3 -C8 cycloalkyl, C5 -C7 cycloalkenyl, or ar1, which is optionally substituted with one or more substituent(s) independently selected from the group consisting of C1 -C4 alkyl, C2 -C4 alkenyl, hydroxy, C3 -C8 cycloalkyl, C5 -C7 cycloalkenyl, and ar1 ; ar1 is selected from the group consisting of 1-napthyl, 2-napthyl, 1-indolyl, 2-indolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl and phenyl, having one or more substituent(s) independently selected from the group consisting of hydrogen, halo, hydroxy, nitro, trifluoromethyl, C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C2 -C4 alkenyloxy, phenoxy, benzyloxy, and amino; X is O, NH, NR1, S, CH, CR1, or CR1 R3 ; Y is a direct bond, C1 -C6 straight or branched chain alkyl, or C2 -C6 straight or branched chain alkenyl; wherein said alkyl or alkenyl is optionally substituted with one or more substituent(s) independently selected from the group consisting of C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C3 -C8 cycloalkyl, C5 -C7 cycloalkenyl, hydroxy, carbonyl oxygen, and ar; wherein said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or ar is optionally substituted with C1 -C4 alkyl, C2 -C4 alkenyl, hydroxy, or carbonyl oxygen; wherein any carbon atom of said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or ar is optionally replaced with O, NH, NR2, S, SO, or SO2 ; R2 is selected from the group consisting of hydrogen, C1 -C4 straight or branched chain alkyl, C3 -C4 straight or branched chain alkenyl or alkynyl, and C1 -C4 bridging alkyl wherein a bridge is formed between the nitrogen and a carbon atom of said alkyl or alkenyl chain having said heteroatom to form a ring, wherein said ring is optionally fused to an ar group; Z is an aromatic amine or a tertiary amine oxidized to a corresponding n-oxide; said aromatic amine is pyridyl, pyrimidyl, quinolinyl, or isoquinolinyl, which is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of halo, hydroxy, nitro, trifluoromethyl, C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C1 -C4 alkoxy, C2 -C4 alkenyloxy, phenoxy, benzyloxy, and amino; said tertiary amine is NR4 R5 R6, wherein R4, R5, and R6 are independently selected from the group consisting of C1 -C6 straight or branched chain alkyl and C2 -C6 straight or branched chain alkenyl; wherein said alkyl or alkenyl is optionally substituted with one or more substituent(s) independently selected from the group consisting of C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C3 -C8 cycloalkyl, C5 -C7 cycloalkenyl, hydroxy, carbonyl oxygen, and ar; wherein said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or ar is optionally substituted with C1 -C4 alkyl, C2 -C4 alkenyl, hydroxy, or carbonyl oxygen; wherein any carbon atom of said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or ar is optionally replaced with O, NH, NR1, S, SO, or SO2 ; ar is selected from the group consisting of pyrrolidinyl, pyridyl, pyrimidyl, pyrazyl, pyridazyl, quinolinyl, and isoquinolinyl; and R1 and R3 are independently hydrogen, C1 -C4 straight or branched chain alkyl, C3 -C4 straight or branched chain alkenyl or alkynyl, or Y--Z. 7. The method of
3-(2-Pyridyl)-1-propyl(2S)-1-(1,1-Dimethyl-1,2-dioxo-pentyl)-2-pyrrolidinec
arboxylate, n-oxide; 3-(3-Pyridyl)-1-propyl(2S)-1-(1,1-Dimethyl-1,2-dioxo-pentyl)-2-pyrrolidinec
arboxylate, n-oxide; 3-(4-Pyridyl)-1-propyl(2S)-1-(1,1-Dimethyl-1,2-dioxo-pentyl)-2-pyrrolidinec
arboxylate, n-oxide; 3-(2-Quinolyl)-1-propyl(2S)-1-(1,1-Dimethyl-1,2-dioxo-pentyl)-2-pyrrolidine
carboxylate, n-oxide; 3-(3-Quinolyl)-1-propyl(2S)-1-(1,1-Dimethyl-1,2-dioxo-pentyl)-2-pyrrolidine
carboxylate, n-oxide; and 3-(4-Quinolyl)-1-propyl(2S)-1-(1,1-Dimethyl-1,2-dioxo-pentyl)-2-pyrrolidine
carboxylate, n-oxide; or a pharmaceutically acceptable salt, ester, or solvate thereof.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1. Field of Invention
This invention relates to pharmaceutical compositions and methods for treating alopecia and promoting hair growth using low molecular weight, small molecule N-oxides of heterocyclic esters, amides, thioesters, or ketones.
2. Description of Related Art
Hair loss occurs in a variety of situations. These situations include male pattern alopecia, alopecia senilis, alopecia areata, diseases accompanied by basic skin lesions or tumors, and systematic disorders such as nutritional disorders and internal secretion disorders. The mechanisms causing hair loss are very complicated, but in some instances can be attributed to aging, genetic disposition, the activation of male hormones, the loss of blood supply to hair follicles, and scalp abnormalities.
The immunosuppressant drugs FK506, rapamycin and cyclosporin are well known as potent T-cell specific immunosuppressants, and are effective against graft rejection after organ transplantation. It has been reported that topical, but not oral, application of FK506 (Yamamoto et al., J. Invest. Dermatol., 1994, 102, 160-164; Jiang et al., J. Invest. Dermatol. 1995, 104, 523-525) and cyclosporin (Iwabuchi et al., J. Dermatol. Sci. 1995, 9, 64-69) stimulates hair growth in a dose-dependent manner. One form of hair loss, alopecia areata, is known to be associated with autoimmune activities; hence, topically administered immunomodulatory compounds are expected to demonstrate efficacy for treating that type of hair loss. The hair growth stimulating effects of FK506 have been the subject of an international patent filing covering FK506 and structures related thereto for hair growth stimulation (Honbo et al., EP 0 423 714 A2). Honbo et al. discloses the use of relatively large tricyclic compounds, known for their immunosuppressive effects, as hair revitalizing agents.
The hair growth and revitalization effects of FK506 and related agents are disclosed in many U.S. patents (Goulet et al., U.S. Pat. No. 5,258,389; Luly et al., U.S. Pat. No. 5,457,111; Goulet et al., U.S. Pat. No. 5,532,248; Goulet et al., U.S. Pat. No. 5,189,042; and Ok et al., U.S. Pat. No. 5,208,241; Rupprecht et al., U.S. Pat. No. 5,284,840; Organ et al., U.S. Pat. No. 5,284,877). These patents claim FK506 related compounds. Although they do not claim methods of hair revitalization, they disclose the known use of FK506 for effecting hair growth. Similar to FK506 (and the claimed variations in the Honbo et al. patent), the compounds claimed in these patents are relatively large. Further, the cited patents relate to immunomodulatory compounds for use in autoimmune related diseases, for which FK506's efficacy is well known.
Other U.S. patents disclose the use of cyclosporin and related compounds for hair revitalization (Hauer et al., U.S. Pat. No. 5,342,625; Eberle, U.S. Pat. No. 5,284,826; Hewitt et al., U.S. Pat. No. 4,996,193). These patents also relate to compounds useful for treating autoimmune diseases and cite the known use of cyclosporin and related immunosuppressive compounds for hair growth.
However, immunosuppressive compounds by definition suppress the immune system and also exhibit other toxic side effects. Accordingly, there is a need for non-immunosuppressant, small molecule compounds which are useful as hair revitalizing compounds.
Hamilton and Steiner disclose in U.S. Pat. No. 5,614,547 novel pyrrolidine carboxylate compounds which bind to the immunophilin FKBP12 and stimulate nerve growth, but which lack immunosuppressive effects. Unexpectedly, it has been discovered that these non-immunosuppressant compounds promote hair growth with an efficacy similar to FK506. Yet their novel small molecule structure and non-immunosuppressive properties differentiate them from FK506 and related immunosuppressive compounds found in the prior art.
The present invention relates to a method for treating alopecia or promoting hair growth in an animal, which comprises administering to said animal an effective amount of an N-oxide of a heterocyclic ester, amide, thioester, or ketone.
The present invention further relates to a pharmaceutical composition which comprises:
(i) an effective amount of an N-oxide of a heterocyclic ester, amide, thioester, or ketone for treating alopecia or promoting hair growth in an animal; and
(ii) a pharmaceutically acceptable carrier.
The N-oxides of heterocyclic esters, amides, thioesters, or ketones used in the inventive methods and pharmaceutical compositions have an affinity for FKBP-type immunophilins and do not exert any significant immunosuppressive activity.
FIG. 1 is a photograph of C57 Black 6 mice before being shaved for the hair regeneration experiment.
FIG. 2 is a photograph of mice treated with a vehicle after six weeks. FIG. 2 shows that less than 3% of the shaved area is covered with new hair growth when the vehicle (control) is administered.
FIG. 3 is a photograph of mice treated with 10 μM of GPI 1046, a related non-immunosuppressive neuro-immunophilin FKBP ligand, after six weeks. FIG. 3 shows the remarkable effects of neuro-immunophilin FKBP ligands, wherein 90% of the shaved area is covered with new hair growth.
FIG. 4 is a photograph of mice treated with 30 μM of GPI 1046, a related non-immunosuppressive neuro-immunophilin FKBP ligand, after six weeks. FIG. 4 shows the remarkable ability of these compounds to achieve, essentially, complete hair regrowth in the shaved area.
FIG. 5 is a bar graph depicting the relative hair growth indices for C57 Black 6 mice treated with a vehicle, FK506, and various non-immunosuppressive neuroimmunophilin FKBP ligands 14 days after treatment with each identified compound. FIG. 5 demonstrates the remarkable early hair growth promoted by a wide variety of non-immunosuppressive neuroimmunophilin FKBP ligands.
"Alopecia" refers to deficient hair growth and partial or complete loss of hair, including without limitation androgenic alopecia (male pattern baldness), toxic alopecia, alopecia senilis, alopecia areata, alopecia pelada and trichotillomania. Alopecia results when the pilar cycle is disturbed. The most frequent phenomenon is a shortening of the hair growth or anagen phase due to cessation of cell proliferation. This results in an early onset of the catagen phase, and consequently a large number of hairs in the telogen phase during which the follicles are detached from the dermal papillae, and the hairs fall out. Alopecia has a number of etiologies, including genetic factors, aging, local and systemic diseases, febrile conditions, mental stresses, hormonal problems, and secondary effects of drugs.
"GPI 1605" refers to a compound of formula ##STR1##
"GPI 1046" refers to 3-(3-pyridyl)-1-propyl(2s)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinec arboxylate, a compound of formula ##STR2##
"GPI 1312" refers to a compound of formula ##STR3##
"GPI 1572" refers to a compound of formula ##STR4##
"GPI 1389" refers to a compound of formula ##STR5##
"GPI 1511" refers to a compound of formula ##STR6##
"GPI 1234" refers to a compound of formula ##STR7##
"Isomers" refer to different compounds that have the same molecular formula. "Stereoisomers" are isomers that differ only in the way the atoms are arranged in space. "Enantiomers" are a pair of stereoisomers that are non-superimposable mirror images of each other. "Diastereoisomers" are stereoisomers which are not mirror images of each other. "Racemic mixture" means a mixture containing equal parts of individual enantiomers. "Non-racemic mixture" is a mixture containing unequal parts of individual enantiomers or stereoisomers.
"Pharmaceutically acceptable salt, ester, or solvate" refers to a salt, ester, or solvate of a subject compound which possesses the desired pharmacological activity and which is neither biologically nor otherwise undesirable. A salt, ester, or solvate can be formed with inorganic acids such as acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, gluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, naphthylate, 2-naphthalenesulfonate, nicotinate, oxalate, sulfate, thiocyanate, tosylate and undecanoate. Examples of base salts, esters, or solvates include ammonium salts; alkali metal salts, such as sodium and potassium salts; alkaline earth metal salts, such as calcium and magnesium salts; salts with organic bases, such as dicyclohexylamine salts; N-methyl-D-glucamine; and salts with amino acids, such as arginine, lysine, and so forth. Also, the basic nitrogen-containing groups can be quarternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl, and diamyl sulfates; long chain halides, such as decyl, lauryl, myristyl, and stearyl chlorides, bromides, and iodides; aralkyl halides, such as benzyl and phenethyl bromides; and others. Water or oil-soluble or dispersible products are thereby obtained.
"Pilar cycle" refers to the life cycle of hair follicles, and includes three phases:
(1) the anagen phase, the period of active hair growth which, insofar as scalp hair is concerned, lasts about three to five years;
(2) the catagen phase, the period when growth stops and the follicle atrophies which, insofar as scalp hair is concerned, lasts about one to two weeks; and
(3) the telogen phase, the rest period when hair progressively separates and finally falls out which, insofar as scalp hair is concerned, lasts about three to four months.
Normally 80 to 90 percent of the follicles are in the anagen phase, less than 1 percent being in the catagen phase, and the rest being in the telogen phase. In the telogen phase, hair is uniform in diameter with a slightly bulbous, non-pigmented root. By contrast, in the anagen phase, hair has a large colored bulb at its root.
"Promoting hair growth" refers to maintaining, inducing, stimulating, accelerating, or revitalizing the germination of hair.
"Treating alopecia" refers to:
(i) preventing alopecia in an animal which may be predisposed to alopecia; and/or
(ii) inhibiting, retarding or reducing alopecia; and/or
(iii) promoting hair growth; and/or
(iv) prolonging the anagen phase of the hair cycle; and/or
(v) converting vellus hair to growth as terminal hair. Terminal hair is coarse, pigmented, long hair in which the bulb of the hair follicle is seated deep in the dermis. Vellus hair, on the other hand, is fine, thin, non-pigmented short hair in which the hair bulb is located superficially in the dermis. As alopecia progresses, the hairs change from the terminal to the vellus type.
The present invention relates to a method for treating alopecia or promoting hair growth in an animal, which comprises administering to said animal an effective amount of an N-oxide of a heterocyclic ester, amide, thioester, or ketone.
The inventive method is particularly useful for treating male pattern alopecia, alopecia senilis, alopecia areata, alopecia resulting from skin lesions or tumors, alopecia resulting from cancer therapy such as chemotherapy and radiation, and alopecia resulting from systematic disorders such as nutritional disorders and internal secretion disorders.
The present invention also relates to a pharmaceutical composition comprising:
(i) an effective amount of an N-oxide of a heterocyclic ester, amide, thioester, or ketone for treating alopecia or promoting hair growth in an animal; and
(ii) a pharmaceutically acceptable carrier.
The N-oxides of heterocyclic esters, amides, thioesters, and ketones used in the methods and pharmaceutical compositions of the present invention are low molecular weight, small molecule compounds having an affinity for FKBP-type immunophilins, such as FKBP12. When an N-oxide of a heterocyclic ester, amide, thioester, or ketone binds to an FKBP-type immunophilin, it has been found to inhibit the prolyl-peptidyl cis-trans isomerase, or rotamase, activity of the binding protein. Unexpectedly, these compounds have also been found to stimulate hair growth. The compounds are devoid of any significant immunosuppressive activity.
The N-oxide of a heterocyclic ester, amide, thioester, or ketone may be a compound of formula I ##STR8##
or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
A and B are taken together, with the nitrogen and carbon atoms to which they are respectively attached, to form a 5-7 membered saturated or unsaturated heterocyclic ring containing any combination of CH, CH2, O, SO, SO2, N, NH and NR1 ;
W is O, S, CH2, or H2 ;
R is C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C3 -C8 cycloalkyl, C5 -C7 cycloalkenyl, or Ar1, which is optionally substituted with one or more substituent(s) independently selected from the group consisting of C1 -C4 alkyl, C2 -C4 alkenyl, hydroxy, C3 -C8 cycloalkyl, C5 -C7 cycloalkenyl, and Ar2 ;
Ar1 and Ar2 are independently selected from the group consisting of 1-napthyl, 2-napthyl, 1-indolyl, 2-indolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl and phenyl, having one or more substituent (s) independently selected from the group consisting of hydrogen, halo, hydroxy, nitro, trifluoromethyl, C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C2 -C4 alkenyloxy, phenoxy, benzyloxy, and amino;
X is O, NH, NR1, S, CH, CR1, or CR1 R3 ;
Y is a direct bond, C1 -C6 straight or branched chain alkyl, or C2 -C6 straight or branched chain alkenyl; wherein said alkyl or alkenyl is optionally substituted with one or more substituent(s) independently selected from the group consisting of C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C3 -C8 cycloalkyl, C5 -C7 cycloalkenyl, hydroxy, carbonyl oxygen, and Ar; wherein said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or Ar is optionally substituted with C1 -C4 alkyl, C2 -C4 alkenyl, hydroxy, or carbonyl oxygen; wherein any carbon atom of said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or Ar is optionally replaced with O, NH, NR2, S, SO, or SO2 ;
R2 is selected from the group consisting of hydrogen, C1 -C4 straight or branched chain alkyl, C3 -C4 straight or branched chain alkenyl or alkynyl, and C1 -C4 bridging alkyl wherein a bridge is formed between the nitrogen and a carbon atom of said alkyl or alkenyl chain containing said heteroatom to form a ring, wherein said ring is optionally fused to an Ar group;
Z is an aromatic amine or a tertiary amine oxidized to a corresponding N-oxide;
said aromatic amine is selected from the group consisting of pyridyl, pyrimidyl, quinolinyl, or isoquinolinyl, which is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of halo, hydroxy, nitro, trifluoromethyl, C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C1 -C4 alkoxy, C2 -C4 alkenyloxy, phenoxy, benzyloxy, and amino;
said tertiary amine is NR4 R5 R6, wherein R4, R5, and R6 are independently selected from the group consisting of C1 -C6 straight or branched chain alkyl or C2 -C6 straight or branched chain alkenyl optionally substituted with one or more substituent(s) independently selected from the group consisting of C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C3 -C8 cycloalkyl, C5 -C7 cycloalkenyl, hydroxy, carbonyl oxygen, and Ar; wherein said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or Ar is optionally substituted with C1 -C4 alkyl, C2 -C4 alkenyl, hydroxy, or carbonyl oxygen; wherein any carbon atom of said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or Ar is optionally replaced with O, NH, NR1, S, SO, or SO2 ;
Ar is selected from the group consisting of pyrrolidinyl, pyridyl, pyrimidyl, pyrazyl, pyridazyl, quinolinyl, and isoquinolinyl; and
R1 and R3 are independently hydrogen, C1 -C4 straight or branched chain alkyl, C3 -C4 straight or branched chain alkenyl or alkynyl, or Y--Z.
Additionally, the N-oxide of a heterocyclic ester, amide, thioester, or ketone may be a compound of formula II ##STR9##
or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
E, F, G and J are independently CH2, O, S, SO, SO2, NH or NR1 ;
W is O, S, CH2, or H2 ;
R is C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C3 -C8 cycloalkyl, C5 -C7 cycloalkenyl, or Ar1, which is optionally substituted with one or more substituent(s) independently selected from the group consisting of C1 -C4 alkyl, C2 -C4 alkenyl, hydroxy, C3 -C8 cycloalkyl, C5 -C7 cycloalkenyl, and Ar1 ;
Ar1 is selected from the group consisting of 1-napthyl, 2-napthyl, 1-indolyl, 2-indolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, and phenyl, having one or more substituent(s) independently selected from the group consisting of hydrogen, halo, hydroxy, nitro, trifluoromethyl, C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C2 -C4 alkenyloxy, phenoxy, benzyloxy, and amino;
X is O, NH, NR1, S, CH, CR1, or CR1 R3 ;
Y is a direct bond, C1 -C6 straight or branched chain alkyl, or C2 -C6 straight or branched chain alkenyl; wherein said alkyl or alkenyl is optionally substituted with one or more substituent(s) independently selected from the group consisting of C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C3 -C8 cycloalkyl, C5 -C7 cycloalkenyl, hydroxy, carbonyl oxygen, and Ar; wherein said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or Ar is optionally substituted with C1 -C4 alkyl, C2 -C4 alkenyl, hydroxy, or carbonyl oxygen; wherein any carbon atom of said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or Ar is optionally replaced with O, NH, NR2, S, SO, or SO2 ;
R2 is selected from the group consisting of hydrogen, C1 -C4 straight or branched chain alkyl, C3 -C4 straight or branched chain alkenyl or alkynyl, and C1 -C4 bridging alkyl wherein a bridge is formed between the nitrogen and a carbon atom of said alkyl or alkenyl chain containing said heteroatom to form a ring, wherein said ring is optionally fused to an Ar group;
Z is an aromatic amine or a tertiary amine oxidized to a corresponding N-oxide;
said aromatic amine is pyridyl, pyrimidyl, quinolinyl, and isoquinolinyl, which is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of halo, hydroxy, nitro, trifluoromethyl, C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C1 -C4 alkoxy, C2 -C4 alkenyloxy, phenoxy, benzyloxy, and amino;
said tertiary amine is NR4 R5 R6, wherein R4, R5, and R6 are independently selected from the group consisting of C1 -C6 straight or branched chain alkyl and C2 -C6 straight or branched chain alkenyl; wherein said alkyl or alkenyl is optionally substituted with one or more substituent(s) independently selected from the group consisting of C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C3 -C3 cycloalkyl, C5 -C7 cycloalkenyl, hydroxy, carbonyl oxygen, and Ar; wherein said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or Ar is optionally substituted with C1 -C4 alkyl, C2 -C4 alkenyl, hydroxy, or carbonyl oxygen; wherein any carbon atom of said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or Ar is optionally replaced with O, NH, NR1, S, SO, or SO2 ;
Ar is selected from the group consisting of pyrrolidinyl, pyridyl, pyrimidyl, pyrazyl, pyridazyl, quinolinyl, and isoquinolinyl; and
R1 and R3 are independently hydrogen, C1 -C4 straight or branched chain alkyl, C3 -C4 straight or branched chain alkenyl or alkynyl, or Y--Z.
The N-oxide of a heterocyclic ester, amide, thioester, or ketone may further be a compound of formula III ##STR10##
or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
E, F, and G are independently CH2, O, S, SO, SO2, NH or NR1 ;
W is O, S, CH2, or H2 ;
R is C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C3 -C8, cycloalkyl, C5 -C7 cycloalkenyl, or Ar1, which is optionally substituted with one or more substituent(s) independently selected from the group consisting of C1 -C4 alkyl, C2 -C4 alkenyl, hydroxy, C3 -C8 cycloalkyl, C5 -C7 cycloalkenyl, and Ar1 ;
Ar1 is selected from the group consisting of 1-napthyl, 2-napthyl, 1-indolyl, 2-indolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl and phenyl, having one or more substituent(s) independently selected from the group consisting of hydrogen, halo, hydroxy, nitro, trifluoromethyl, C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C2 -C4 alkenyloxy, phenoxy, benzyloxy, and amino;
X is O, NH, NR1, S, CH, CR1, or CR1 R3 ;
Y is a direct bond, C1 -C6 straight or branched chain alkyl, or C2 -C6 straight or branched chain alkenyl; wherein said alkyl or alkenyl is optionally substituted with one or more substituent(s) independently selected from the group consisting of C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C3 -C8 cycloalkyl, C5 -C4 cycloalkenyl, hydroxy, carbonyl oxygen, and Ar; wherein said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or Ar is optionally substituted with C1 -C4 alkyl, C2 -C4 alkenyl, hydroxy, or carbonyl oxygen; wherein any carbon atom of said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or Ar is optionally replaced with O, NH, NR2, S, SO, or SO2 ;
R2 is selected from the group consisting of hydrogen, C1 -C4 straight or branched chain alkyl, C3 -C4 straight or branched chain alkenyl or alkynyl, and C1 -C4 bridging alkyl wherein a bridge is formed between the nitrogen and a carbon atom of said alkyl or alkenyl chain containing said heteroatom to form a ring, wherein said ring is optionally fused to an Ar group;
Z is an aromatic amine or a tertiary amine oxidized to a corresponding N-oxide;
said aromatic amine is pyridyl, pyrimidyl, quinolinyl, or isoquinolinyl, which is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of halo, hydroxy, nitro, trifluoromethyl, C1 -C6 straight or branched chain alkyl, C2-C6 straight or branched chain alkenyl, C1 -C4 alkoxy, C2 -C4 alkenyloxy, phenoxy, benzyloxy, and amino;
said tertiary amine is NR4 R5 R6, wherein R4, R5, and R6 are independently selected from the group consisting of C1 -C6 straight or branched chain alkyl and C2 -C6 straight or branched chain alkenyl; wherein said alkyl or alkenyl is optionally substituted with one or more substituent(s) independently selected from the group consisting of C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C3 -C8 cycloalkyl, C5 -C7 cycloalkenyl, hydroxy, carbonyl oxygen, and Ar; wherein said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or Ar is optionally substituted with C1 -C4 alkyl, C2 -C4 alkenyl, hydroxy, or carbonyl oxygen; wherein any carbon atom of said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or Ar is optionally replaced with O, NH, NR1, S, SO, or SO2 ;
Ar is selected from the group consisting of pyrrolidinyl, pyridyl, pyrimidyl, pyrazyl, pyridazyl, quinolinyl, and isoquinolinyl; and
R1 and R3 are independently hydrogen, C1 -C4 straight or branched chain alkyl, C3 -C4 straight or branched chain alkenyl or alkynyl, or Y--Z.
Moreover, the N-oxide of a heterocyclic ester, amide, thioester, or ketone may be a compound of formula IV ##STR11##
or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
n is 1, 2, or 3, forming a 5-7 member heterocyclic ring;
W is O, S, CH2, or H2 ;
R is C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C3 -C8 cycloalkyl, C5 -C7 cycloalkenyl, or Ar1 , which is optionally substituted with one or more substituent(s) independently selected from the group consisting of C1 -C4 alkyl, C2 -C4 alkenyl, hydroxy, C3 -C8 cycloalkyl, C5 -C7 cycloalkenyl, and Ar1 ;
Ar1 is selected from the group consisting of 1-napthyl, 2-napthyl, 1-indolyl, 2-indolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl and phenyl, having one or more substituent(s) independently selected from the group consisting of hydrogen, halo, hydroxy, nitro, trifluoromethyl, C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C2 -C4 alkenyloxy, phenoxy, benzyloxy, and amino;
X is O, NH, NR1, S, CH, CR1, or CR1 R3 ;
Y is a direct bond, C1 -C6 straight or branched chain alkyl, or C2 -C6 straight or branched chain alkenyl; wherein said alkyl or alkenyl is optionally substituted with one or more substituent(s) independently selected from the group consisting of C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C3 -C8 cycloalkyl, C5 -C7 cycloalkenyl, hydroxy, carbonyl oxygen, and Ar; wherein said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or Ar is optionally substituted with C1 -C4 alkyl, C2 -C4 alkenyl, hydroxy, or carbonyl oxygen; wherein any carbon atom of said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or Ar is optionally replaced with O, NH, NR2, S, SO, or SO2 ;
R2 is selected from the group consisting of hydrogen, C1 -C4 straight or branched chain alkyl, C3 -C4 straight or branched chain alkenyl or alkynyl, and C1 -C4 bridging alkyl wherein a bridge is formed between the nitrogen and a carbon atom of said alkyl or alkenyl chain containing said heteroatom to form a ring, wherein said ring is optionally fused to an Ar group;
Z is an aromatic amine or a tertiary amine oxidized to a corresponding N-oxide;
said aromatic amine is pyridyl, pyrimidyl, quinolinyl, or isoquinolinyl, which is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of halo, hydroxy, nitro, trifluoromethyl, C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C1 -C4 alkoxy, C2 -C4 alkenyloxy, phenoxy, benzyloxy, and amino;
said tertiary amine is NR4 R5 R6, wherein R4, R5, and R6 are independently selected from the group consisting of C1 -C6 straight or branched chain alkyl and C2 -C6 straight or branched chain alkenyl; wherein said alkyl or alkenyl is optionally substituted with one or more substituent(s) independently selected from the group consisting of C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C3 -C8 cycloalkyl, C5 -C7 cycloalkenyl, hydroxy, carbonyl oxygen, and Ar; wherein said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or Ar is optionally substituted with C1 -C4 alkyl, C2 -C4 alkenyl, hydroxy, or carbonyl oxygen; wherein any carbon atom of said alkyl, alkenyl, cycloalkyl, cycloalkenyl, or Ar is optionally replaced with O, NH, NR1, S, SO, or SO2 ;
Ar is selected from the group consisting of pyrrolidinyl, pyridyl, pyrimidyl, pyrazyl, pyridazyl, quinolinyl, and isoquinolinyl; and
R1 and R3 hydrogen, C1 -C4 straight or branched chain alkyl, C3 -C4 straight or branched chain alkenyl or alkynyl, or Y--Z.
Examples of the compounds of formula IV when W is O are presented in Table I.
| TABLE I |
| ##STR12## |
| No. n X Y Z R |
| 1 1 0 (CH2)3 3-Pyridyl N-oxide 1,1-dimethylpropyl |
| 2 1 0 (CH2)3 2-Pyridyl N-oxide 1,1-dimethylpropyl |
| 3 1 0 (CH2)3 4-Pyridyl N-oxide 1,1-dimethylpropyl |
| 4 1 0 (CH2)3 2-Quinolyl N-oxide 1,1-dimethylpropyl |
| 5 1 0 (CH2)3 3-Quinolyl N-oxide 1,1-dimethylpropyl |
| 6 1 0 (CH2)3 4-Quinolyl N-oxide 1,1-dimethylpropyl |
Preferred compounds of formula IV may be selected from the group consisting of:
3-(2-Pyridyl)-1-propyl(2S) -1-(1,1-Dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate, N-oxide;
3-(3-Pyridyl)-1-propyl(2S)-1-(1,1-Dimethyl-1,2-dioxopentyl)-2-pyrrolidineca rboxylate, N-oxide;
3-(4-Pyridyl) -1-propyl(2S) -1-(1,1-Dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate, N-oxide;
3-(2-Quinolyl)-1-propyl(2S) -1-(1, l-Dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate, N-oxide;
3-(3-Quinolyl)-1-propyl(2S)-1-(1,1-Dimethyl-1,2-dioxopentyl)-2-pyrrolidinec arboxylate, N-oxide;
3-(4-Quinolyl)-1-propyl(2S)-1-(1,1-Dimethyl-1,2-dioxopentyl)-2-pyrrolidinec arboxylate, N-oxide; and
pharmaceutically acceptable salts, esters, and solvates thereof.
The N-oxide of a heterocyclic ester, amide, thioester, or ketone may further be a compound of formula V ##STR13##
or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
V is C, N, or S;
A and B, taken together with V and the carbon atom to which they are respectively attached, form a 5-7 membered saturated or unsaturated heterocyclic ring containing, in addition to V, one or more heteroatom(s) independently selected from the group consisting of O, S, SO, SO2, N, NH, and NR7 ;
R7 is either C1 -C9 straight or branched chain alkyl, C2 -C9 straight or branched chain alkenyl, C3 -C9 cycloalkyl, C5 -C7 cycloalkenyl, or Ar3, wherein R7 is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of halo, haloalkyl, carbonyl, carboxy, hydroxy, nitro, trifluoromethyl, C1 -C6 straight or branched chain alkyl, C2 -C6 straight or branched chain alkenyl, C1 -C4 alkoxy, C2 -C4 alkenyloxy, phenoxy, benzyloxy, thioalkyl, alkylthio, sulfhydryl, amino, alkylamino, aminoalkyl, aminocarboxyl, and Ar4 ;
Ar3 and Ar4 are independently an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring; wherein the individual ring size is 5-8 members; wherein said heterocyclic ring contains 1-6 heteroatom(s) independently selected from the group consisting of O, N, and S; and
R, W, X, Y, and Z are as defined in Formula I above.
All the compounds of Formulas I-V possess asymmetric centers and thus can be produced as mixtures of stereoisomers or as individual R- and S-stereoisomers. The individual stereoisomers may be obtained by using an optically active starting material, by resolving a racemic or non-racemic mixture of an intermediate at some appropriate stage of the synthesis, or by resolving the compounds of Formulas I-V. It is understood that the compounds of Formulas I-V encompass individual stereoisomers as well as mixtures (racemic and non-racemic) of stereoisomers. Preferably, S-stereoisomers are used in the pharmeceutical compositions and methods of the present invention.
The compounds used in the inventive methods and pharmaceutical compositions have an affinity for the FK506 binding protein, particularly FKBP12. The inhibition of the prolyl peptidyl cis-trans isomerase activity of FKBP may be measured as an indicator of this affinity.
Inhibition of the peptidyl-prolyl isomerase (rotamase) activity of the compounds used in the inventive methods and pharmaceutical compositions can be evaluated by known methods described in the literature (Harding et al., Nature, 1989, 341:758-760; Holt et al. J. Am. Chem. Soc., 115:9923-9938). These values are obtained as apparent Ki 's and are presented for representative compounds in TABLE II.
The cis-trans isomerization of an alanine-proline bond in a model substrate, N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide, is monitored spectrophotometrically in a chymotrypsin-coupled assay, which releases para-nitroanilide from the trans form of the substrate. The inhibition of this reaction caused by the addition of different concentrations of inhibitor is determined, and the data is analyzed as a change in first-order rate constant as a function of inhibitor concentration to yield the apparent Ki values.
In a plastic cuvette are added 950 mL of ice cold assay buffer (25 mM HEPES, pH 7.8, 100 mM NaCl), 10 mL of FKBP (2.5 mM in 10 mM Tris-Cl pH 7.5, 100 mM NaCl, 1 mM dithiothreitol), 25 mL of chymotrypsin (50 mg/ml in 1 mM HCl) and 10 mL of test compound at various concentrations in dimethyl sulfoxide. The reaction is initiated by the addition of 5 mL of substrate (succinyl-Ala-Phe-Pro-Phe-para-nitroanilide, 5 mg/mL in 2.35 mM LiCl in trifluoroethanol).
The absorbance at 390 nm versus time is monitored for 90 seconds using a spectrophotometer and the rate constants are determined from the absorbance versus time data files.
Data is presented in Table II for 3-(3-Pyridyl)-1-propyl(2S)-1-(1,1-Dimethyl-1,2-dioxopentyl)-2-pyrrolidine- carboxylate, N-oxide (compound 1) and its parent (unoxidized) compound.
| TABLE II |
| In Vitro Test Results - Formulas I to V |
| Compound Ki (nM) |
| Parent 7.5 |
| 1 225 |
To effectively treat alopecia or promote hair growth, the compounds used in the inventive methods and pharmaceutical compositions must readily affect the targeted areas. For these purposes, the compounds are preferably administered topically to the skin.
For topical application to the skin, the compounds can be formulated into suitable ointments containing the compounds suspended or dissolved in, for example, mixtures with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, the compounds can be formulated into suitable lotions or creams containing the active compound suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
Other routes of administration known in the pharmaceutical art are also contemplated by this invention.
Dosage levels on the order of about 0.1 mg to about 10,000 mg of the active ingredient compound are useful in the treatment of the above conditions, with preferred levels of about 0.1 mg to about 1,000 mg. The specific dose level for any particular patient will vary depending upon a variety of factors, including the activity of the specific compound employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the rate of excretion; drug combination; the severity of the particular disease being treated; and the form of administration. Typically, in vitro dosage-effect results provide useful guidance on the proper doses for patient administration. Studies in animal models are also helpful. The considerations for determining the proper dose levels are well known in the art.
The compounds can be administered with other hair revitalizing agents. Specific dose levels for the other hair revitalizing agents will depend upon the factors previously stated and the effectiveness of the drug combination.
The following examples are illustrative of the present invention and are not intended to be limitations thereon. Unless otherwise indicated, all percentages are based upon 100% by weight of the final composition.
PAC Synthesis of 3-(3-pyridyl)-1-propyl(2S)-1-(3,3-Dimethyl-1,2-dioxopentyl)-2-pyrrolidinec arboxylate, N-oxide (1)Methyl(2S)-1-(1.2-dioxo-2-methoxyethyl)-2-pyrrolidinecarboxylate
A solution of L-proline methyl ester hydrochloride (3.08 g; 18.60 mmol) in dry methylene chloride was cooled to 0°C and treated with triethylamine (3.92 g; 38.74 mmol; 2.1 eq). After stirring the formed slurry under a nitrogen atmosphere for 15 minutes, a solution of methyl oxalyl chloride (3.20 g; 26.12 mmol) in methylene chloride (45 mL) was added dropwise. The resulting mixture was stirred at 0°C for 1.5 hour. After filtering to remove solids, the organic phase was washed with water, dried over MgSO4 and concentrated. The crude residue was purified on a silica gel column, eluting with 50% ethyl acetate in hexane, to obtain 3.52 g (88%) of the product as a reddish oil. Mixture of cis-trans amide rotamers; data for trans rotamer given. 1 H NMR (CDCl3): δ 1.93 (dm, 2H); 2.17 (m, 2H); 3.62 (m, 2H); 3.71 (s, 3H); 3.79, 3.84 (s, 3H total); 4.86 (dd, 1H, J=8.4, 3.3).
Methyl (2S)-1-(1,2-dioxo-3,3-dimethylpentyl)-2-pyrrolidinecarboxylate
A solution of methyl (2S)-1-(1,2-dioxo-2-methoxyethyl)-2-pyrrolidinecarboxylate (2.35 g; 10.90 mmol) in 30 mL of tetrahydrofuran (THF) was cooled to -78°C and treated with 14.2 mL of a 1.0 M solution of 1,1-dimethylpropylmagnesium chloride in THF. After stirring the resulting homogeneous mixture at -78°C for three hours, the mixture was poured into saturated ammonium chloride (100 mL) and extracted into ethyl acetate. The organic phase was washed with water, dried, and concentrated, and the crude material obtained upon removal of the solvent was purified on a silica gel column, eluting with 25% ethyl acetate in hexane, to obtain 2.10 g (75%) of the oxamate as a colorless oil. 1 H NMR (CDCl3) : δ 0.88 (t, 3H); 1.22, 1.26 (s, 3H each); 1.75 (dm, 2H); 1.87-2.10 (m, 3H); 2.23 (m, 1H); 3.54 (m, 2H); 3.76 (s, 3H); 4.52 (dm, 1H, J=8.4, 3.4).
(2S)-1-(1,2-dioxo-3 3-dimethylpentyl)-2-pyrrolidinecarboxylic acid
A mixture of methyl (2S)-1-(1,2-dioxo-3,3-dimethylpentyl-2-pyrrolidine-carboxylate (2.10 g; 8.23 mmol), 1 N LiOH (15 mL), and methanol (50 mL) was stirred at 0°C for 30 minutes and at room temperature overnight. The mixture was acidified to pH 1 with 1 N HCl, diluted with water, and extracted into 100 mL of methylene chloride. The organic extract was washed with brine and concentrated to deliver 1.73 g (87t) of snow-white solid which did not require further purification. 1 H NMR (CDCl3): d 0.87 (t, 3H); 1.22, 1.25 (s, 3H each); 1.77 (dm, 2H); 2.02 (m, 2H); 2.17 (m, 1H); 2.25 (m, 1H); 3.53 (dd, 2H, J=10.4, 7.3); 4.55 (dd, 1H, J=8.6, 4.1).
3-(3-Pyridyl)-1-propyl(2S)-1-(3 3-dimethyl-1-2-dioxopentyl)-2-pyrrolidinecarboxylate
A mixture of (2S)-1-(1,2-dioxo-3,3-dimethylpentyl)-2-pyrrolidinecarboxylic acid (4.58 g; 19 mmol), 3-pyridinepropanol (3.91 g; 28.5 mmol), dicyclohexylcarbodiimide (6.27 g; 30.4 mmol), camphorsulfonic acid (1.47 g; 6.33 mmol) and 4-dimethyl aminopyridine (773 mg; 6.33 mmol) in methylene chloride (100 mL) was stirred overnight under a nitrogen atmosphere. The reaction mixture was filtered through Celite to remove solids and concentrated in vacuo. The crude material was triturated with several portions of ether, and the ether portions were filtered through Celite to remove solids and concentrated in vacuo. The concentrated filtrate was purified on a flash column (gradient elution, 25% ethyl acetate in hexane to pure ethyl acetate) to obtain 5.47 g (80%) of GPI 1046 as a colorless oil (partial hydrate). 1 H NMR (CDCl3, 300 MHz): δ 0.85 (t, 3H); 1.23, 1.26 (s, 3H each); 1.63-1.89 (m, 2H); 1.90-2.30 (m, 4H); 2.30-2.50 (m, 1H); 2.72 (t, 2H); 3.53 (m, 2H); 4.19 (m, 2H); 4.53 (m, 1H); 7.22 (m, 1H); 7.53 (dd, 1H); 8.45. Analysis calculated for C20 H28 NO4 --0.25 H2 O: C, 65.82; H, 7.87; N, 7.68. Found: C, 66.01; H, 7.85; N, 7.64.
3-(3-Pyridyl)-1-propyl(2S)-1-(3,3-dimethyl-1. 2-dioxopentyl)-2-pyrrolidinecarboxylate, N-oxide (1)
A solution of 3-(3-pyridyl)-1-propyl(2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinec arboxylate (190 mg; 0.52 mmol) and m-chloroperbenzoic acid (160 mg of 57%-86% material, 0.53 mmol) was stirred in methylene chloride (20 mL) at room temperature for 3 hours. The reaction mixture was diluted with methylene chloride and washed twice with 1 N NaOH. The organic extract was dried and concentrated, and the crude material was chromatographed, eluting with 10% methanol in ethyl acetate, to obtain 130 mg of the Compound 1 of Example 1. 1 H NMR (CDCl3, 300 MHz) : δ 0.83 (t, 3H); 1.21 (s, 3H); 1.25 (s, 3H); 1.75-2.23 (m, 8H); 2.69 (t, 2H, J=7.5); 3.52 (t, 2H, J=6.3); 4.17 (dd, 2H, J=6.3); 4.51 (m, 1H); 7.16-7.22 (m, 2H); 8.06-8.11 (m, 2H). Analysis calculated for C20 H28 N2 O5 --0.75 H2 O: C, 61.60; H, 7.63; N, 7.18. Found: C, 61.79; H, 7.58; N, 7.23.
In Vivo Hair Generation Tests With C57 Black 6 Mice
Experiment A: C57 black 6 mice were used to demonstrate the hair revitalizing properties of a low molecular weight, small molecule, non-immunosuppressive neuroimmunophilin FKBP ligand, GPI 1046, which is related to N-oxides of heterocylic esters, amides, thioesters, and ketones. Referring now to FIGS. 1 and 2 of the drawings, C57 black 6 mice, approximately 7 weeks old, had an area of about 2 inches by 2 inches on their hindquarters shaved to remove all existing hair. Care was taken not to nick or cause abrasion to the underlaying dermal layers. The animals were in anagen growth phase, as indicated by the pinkish color of the skin. Referring now to FIGS. 2, 3 and 4, four animals per group were treated by topical administration with 20% propylene glycol vehicle (FIG. 2), 10 μM GPI 1046 (FIG. 3) or 30 μM GPI 1046 (FIG. 4) dissolved in the vehicle. The animals were treated with vehicle or GPI 1046 every 48 hours (3 applications total over the course of 5 days) and the hair growth was allowed to proceed for 6 weeks. Hair growth was quantitated by the percent of shaved area covered by new hair growth during this time period.
FIG. 2 shows that animals treated with vehicle exhibited only a small amount of hair growth in patches or tufts, with less than 3% of the shaved area covered with new growth. In contrast, FIG. 3 shows that animals treated with 10 μM GPI 1046 exhibited dramatic hair growth, covering greater than 90% of the shaved area in all animals. Further, FIG. 4 shows that mice treated with 30 μM GPI 1046 exhibited essentially complete hair regrowth and their shaved areas were indistinguishable from unshaven C57 black 6 mice.
Experiment B: C57 Black 6 mice were used to demonstrate the hair revitalizing properties of various low molecular weight, small molecule, non-immunosuppressive neuroimmunophilin FKBP ligands. C57 Black 6 mice, 55 to 75 days old, had an area of about 2 inches by 2 inches on their hindquarters shaved to remove all existing hair. Care was taken not to nick or cause abrasion to the underlying dermal layers. The animals were in a anagen growth phase when shaved. Five animals per group were treated by topical administration with a vehicle, FK506, or one of the low molecular weight, small molecule, non-immunosuppressive neuroimmunophilin FKBP ligands (GPI 1605, 1046, 1312, 1572, 1389, 1511, and 1234) at a concentration of one micromole per milliliter to the shaved area. The animals were treated three times per week, and hair growth was evaluated 14 days after initiation of treatment. Hair growth was quantitated by the percent of shaved area covered by new hair growth, as scored by a blinded observer, on a scale of 0 (no growth) to five (complete hair regrowth in shaved area).
FIG. 5 shows that after 14 days, the animals treated with vehicle exhibited the beginning of growth in small tufts. In contrast, animals treated with any one of the low molecular weight, small molecule, non-immunosuppressive neuroimmunophilin FKBP ligands exhibited dramatic hair growth.
A lotion comprising the following composition may be prepared.
TBL (%) 95% Ethanol 80.0 an N-oxide of a heterocylic ester, amide, 10.0 thioester, or ketone as defined above α-Tocopherol acetate 0.01 Ethylene oxide (40 mole) adducts of hardened 0.5 castor oil purified water 9.0 perfume and dye q.s.Into 95% ethanol are added an N-oxide of a heterocylic ester, amide, thioester, or ketone, α-tocopherol acetate, ethylene oxide (40 mole) adducts of hardened castor oil, perfume and a dye. The resulting mixture is stirred and dissolved, and purified water is added to the mixture to obtain a transparent liquid lotion.
5 ml of the lotion may be applied once or twice per day to a site having marked baldness or alopecia.
A lotion comprising the following composition may be prepared.
TBL (%) 95% Ethanol 80.0 an N-oxide of a heterocylic ester, amide, 0.005 thioester, or ketone as defined above Hinokitol 0.01 Ethylene oxide (40 mole) adducts of hardened 0.5 castor oil Purified water 19.0 Perfume and dye q.s.Into 95% ethanol are added an N-oxide of a heterocylic ester, amide, thioester, or ketone, hinokitol, ethylene oxide (40 mole) adducts of hardened castor oil, perfume, and a dye. The resulting mixture is stirred, and purified water is added to the mixture to obtain a transparent liquid lotion.
The lotion may be applied by spraying once to 4 times per day to a site having marked baldness or alopecia.
An emulsion may be prepared from A phase and B phase having the following compositions.
TBL (%) (A phase) Whale wax 0.5 Cetanol 2.0 Petrolatum 5.0 Squalane 10.0 Polyoxyethylene (10 mole) monostearate 2.0 Sorbitan monooleate 1.0 an N-oxide of a heterocylic ester, amide, 0.01 thioester, or ketone as defined above (B phase) Glycerine 10.0 Purified water 69.0 Perfume, dye, and preservative q.s.The A phase and the B phase are respectively heated and melted and maintained at 80°C Both phases are then mixed and cooled under stirring to normal temperature to obtain an emulsion.
The emulsion may be applied by spraying once to four times per day to a site having marked baldness or alopecia.
A cream may be prepared from A phase and B phase having the following compositions.
TBL (%) (A Phase) Fluid paraffin 5.0 Cetostearyl alcohol 5.5 Petrolatum 5.5 Glycerine monostearate 33.0 Polyoxyethylene (20 mole) 2-octyldodecyl 3.0 ether Propylparaben 0.3 (B Phase) an N-oxide of a heterocylic ester, amide, 0.8 thioester, or ketone as defined above Glycerine 7.0 Dipropylene glycol 20.0 Polyethylene glycol 4000 5.0 Sodium Hexametaphosphate 0.005 Purified water 44.895The A phase is heated and melted, and maintained at 70°C The B phase is added into the A phase and the mixture is stirred to obtain an emulsion. The emulsion is then cooled to obtain a cream.
The cream may be applied once to 4 times per day to a site having marked baldness or alopecia.
A liquid comprising the following composition may be prepared.
TBL (%) Polyoxyethylene butyl ether 20.0 Ethanol 50.0 an N-oxide of a heterocylic ester, amide, 0.001 thioester, or ketone as defined above Propylene glycol 5.0 Polyoxyethylene hardened castor oil 0.4 derivative (ethylene oxide 80 mole adducts) Perfume q.s. Purified water q.s.Into ethanol are added polyoxypropylene butyl ether, propylene glycol, polyoxyethylene hardened castor oil, an N-oxide of a heterocylic ester, amide, thioester, or ketone, and perfume. The resulting mixture is stirred, and purified water is added to the mixture to obtain a liquid.
The liquid may be applied once to 4 times per day to a site having marked baldness or alopecia.
A shampoo comprising the following composition may be prepared.
TBL (%) Sodium laurylsulfate 5.0 Triethanolamine laurylsulfate 5.0 Betaine lauryldimethylaminoacetate 6.0 Ethylene glycol distearate 2.0 Polyethylene glycol 5.0 an N-oxide of a heterocylic ester, amide, 5.0 thioester, or ketone as defined above Ethanol 2.0 Perfume 0.3 Purified water 69.7Into 69.7 of purified water are added 5.0 g of sodium laurylsulfate, 5.0 g of triethanolamine laurylsulfate, 6.0 g of betaine lauryldimethyl-aminoacetate. Then a mixture obtained by adding 5.0 g of an N-oxide of a heterocylic ester, amide, thioester, or ketone, 5.0 g of polyethylene glycol, and 2.0 g of ethylene glycol distearate to 2.0 g of ethanol, followed by stirring, and 0.3 g of perfume are successively added. The resulting mixture is heated and subsequently cooled to obtain a shampoo.
The shampoo may be used on the scalp once or twice per day.
A patient is suffering from alopecia senilis. An N-oxide of a heterocylic ester, amide, thioester, or ketone as identified above, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
A patient is suffering from male pattern alopecia. An N-oxide of a heterocylic ester, amide, thioester, or ketone as identified above, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
A patient is suffering from alopecia areata. An N-oxide of a heterocylic ester, amide, thioester, or ketone as identified above, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
A patient is suffering from hair loss caused by skin lesions. An N-oxide of a heterocylic ester, amide, thioester, or ketone as identified above, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
A patient is suffering from hair loss caused by tumors. An N-oxide of a heterocylic ester, amide, thioester, or ketone as identified above, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
A patient is suffering from hair loss caused by a systematic disorder, such as a nutritional disorder or an internal secretion disorder. An N-oxide of a heterocylic ester, amide, thioester, or ketone as identified above, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
A patient is suffering from hair loss caused by chemotherapy. An N-oxide of a heterocylic ester, amide, thioester, or ketone as identified above, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
A patient is suffering from hair loss caused by radiation. An N-oxide of a heterocylic ester, amide, thioester, or ketone as identified above, or a pharmaceutical composition comprising the same, may be administered to the patient. Increased hair growth is expected to occur following treatment.
The invention being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the invention and all such modifications are intended to be included within the scope of the following claims.
Steiner, Joseph P., Hamilton, Gregory S.
| Patent | Priority | Assignee | Title |
| 6429215, | Jun 03 1998 | GLIAMED, INC | N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses |
| 6943187, | Jun 04 1997 | GLIAMED, INC | Pyrrolidine derivative hair growth compositions and uses |
| 7452996, | May 21 2004 | Novartis Vaccines and Diagnostics, Inc. | Substituted quinoline derivatives |
| 7820646, | Jan 05 2007 | Novartis Vaccines and Diagnostics, Inc | Cyclized derivatives as Eg-5 inhibitors |
| Patent | Priority | Assignee | Title |
| 4310461, | Jun 23 1980 | E R SQUIBB & SONS, INC , A CORP OF DE | Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids |
| 4374829, | Dec 11 1978 | Merck & Co., Inc. | Aminoacid derivatives as antihypertensives |
| 4390695, | Jun 23 1980 | E. R. Squibb & Sons, Inc. | Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids |
| 4438031, | Feb 24 1982 | AMERICAN HOME PRODUCTS CORPORATION, A CORP OF DE | N-(Alkylsulfonyl)-L-proline amide and N-(alkylsulfonyl)-2-carboxylic acid amide-indoline derivatives |
| 4531964, | Sep 13 1982 | Nippon Kayaku Kabushiki Kaisha | Heterocyclic compound and a herbicidal composition containing said compound |
| 4574079, | May 27 1983 | BOSTON UNIVERSITY, A NOT FOR PROFIT CORP | Radiolabeled angiotensin converting enzyme inhibitors for radiolabeling mammalian organ sites |
| 4578474, | Jun 23 1980 | E. R. Squibb & Sons, Inc. | Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids |
| 4593102, | Apr 10 1984 | A H ROBINS COMPANY, INCORPORATED, A DE CORP | N-[(amino)alkyl]-1-pyrrolidine, 1-piperidine and 1-homopiperidinecarboxamides (and thiocarboxamides) with sulfur linked substitution in the 2, 3 or 4-position |
| 4808573, | Oct 23 1980 | Schering Corporation | Carboxyalkyl dipeptides and anti-hypertensive use thereof |
| 4818749, | Oct 23 1980 | Schering Corporation | Carboxyalkyl dipeptides and medical use thereof in treating hypertension and congestive heart failure |
| 4996193, | Mar 03 1989 | The Regents of the University of California | Combined topical and systemic method of administration of cyclosporine |
| 5147877, | Apr 18 1991 | MERCK & CO , INC A CORPORATION OF NEW JERSEY | Semi-synthetic immunosuppressive macrolides |
| 5189042, | Aug 22 1991 | MERCK & CO , INC A CORPORATION OF NJ | Fluoromacrolides having immunosuppressive activity |
| 5192773, | Jul 02 1990 | Vertex Pharmaceuticals, Inc.; VERTEX PHARMACEUTICALS INCORPORATED | Immunosuppressive compounds |
| 5208241, | Sep 09 1991 | Merck & Co., Inc.; MERCK CO , INC A CORPORATION OF NJ | N-heteroaryl, N-alkylheteroaryl, N-alkenylheteroaryl and N-alkynylheteroarylmacrolides having immunosuppressive activity |
| 5252579, | Feb 16 1993 | Wyeth | Macrocyclic immunomodulators |
| 5258389, | Nov 09 1992 | Merck Sharp & Dohme Corp | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
| 5284826, | Jul 24 1989 | Novartis AG | 0-hydroxyethyl and acyloxyethyl derivatives of [ser]8 cyclosporins |
| 5284840, | Jun 12 1992 | Merck & Co., Inc.; MERCK & CO , INC | Alkylidene macrolides having immunosuppressive activity |
| 5284877, | Jun 12 1992 | Merck & Co., Inc.; MERCK & CO , INC | Alkyl and alkenyl macrolides having immunosuppressive activity |
| 5292747, | Aug 07 1990 | Hoffman-La Roche Inc. | Substituted pyrroles |
| 5294603, | Sep 12 1980 | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, THE A CORP OF ILLINOIS | Pharmaceutical compositions containing didemnins |
| 5319098, | May 18 1993 | Celgene Corporation | Process for the stereoselective preparation of L-alanyl-L-proline |
| 5330993, | Jul 02 1990 | VERTEX PHARMACEUTICALS, INC , A CORP OF MA | Immunosuppressive compounds |
| 5342625, | Sep 16 1988 | Novartis AG | Pharmaceutical compositions comprising cyclosporins |
| 5359138, | Apr 15 1989 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Poststatin and related compounds or salts thereof |
| 5385908, | Nov 22 1993 | Wyeth | Hindered esters of rapamycin |
| 5385918, | Feb 09 1993 | MILES INC | Aminomethylene-peptides as immunosuppressants |
| 5414083, | Jan 22 1993 | Chemie Linz Gesellschaft m.b.H. | Method for the production of N-cyclic and N,N'-dicyclic ureas and their use as chemical solvents |
| 5424454, | May 18 1993 | Celgene Corporation | Process for the stereoselective preparation of l-alanyl-l-proline |
| 5447915, | Feb 28 1990 | President and Fellows of Harvard College; Dana-Farber Cancer Institute, Inc. | Terminally blocked antiviral peptides |
| 5457111, | Sep 05 1991 | Abbott Laboratories | Macrocyclic immunomodulators |
| 5470878, | Mar 31 1993 | Cell Therapeutics, Inc.; CELL THERAPEUTICS, INC | Cell signaling inhibitors |
| 5472687, | Jul 18 1985 | Topical pyridine N-oxides | |
| 5506228, | Feb 23 1995 | MERCK & CO , INC | 2,6-diaryl pyridazinones with immunosuppressant activity |
| 5516797, | Jul 02 1990 | Vertex Pharmaceuticals, Incorporated | Immunosuppressive compounds |
| 5532248, | May 13 1991 | Merck Co., Inc. | O-aryl,O-alkyl, and O-alkenyl-macrolides having immunosuppressive activity |
| 5543423, | Nov 16 1994 | VERTEX PHARMACEUTICALS INCORPORATED | Amino acid derivatives with improved multi-drug resistance activity |
| 5614547, | Jun 07 1995 | GLIAMED, INC | Small molecule inhibitors of rotamase enzyme |
| 5620971, | May 09 1991 | VERTEX PHARMACEUTICALS INCORPORATED | Biologically active acylated amino acid derivatives |
| 5631017, | Mar 26 1993 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | Topical application of buspirone for treatment of pathological conditions associated with immune responses |
| 5703088, | Aug 21 1989 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses |
| 5714510, | Jul 18 1985 | Topical proxyl composition and method | |
| DE2505114, | |||
| DE3508251, | |||
| DE3931051, | |||
| DE4015255, | |||
| EP420707, | |||
| EP443983, | |||
| EP471135, | |||
| EP494005, | |||
| EP519819, | |||
| EP823419, | |||
| EP12401, | |||
| EP196841, | |||
| EP260118, | |||
| EP333174, | |||
| EP352000, | |||
| EP378318, | |||
| EP405994, | |||
| EP419049, | |||
| EP423714, | |||
| EP468339, | |||
| EP48159, | |||
| EP50800, | |||
| EP564924, | |||
| EP572365, | |||
| EP652229, | |||
| EP73143, | |||
| EP88350, | |||
| GB2247456, | |||
| JP4149166, | |||
| JP5178824, | |||
| WO8800040, | |||
| WO8809789, | |||
| WO8906234, | |||
| WO9012805, | |||
| WO9104985, | |||
| WO9113088, | |||
| WO9200278, | |||
| WO9203472, | |||
| WO9204370, | |||
| WO9216501, | |||
| WO9218478, | |||
| WO9219593, | |||
| WO9219745, | |||
| WO9221313, | |||
| WO9307269, | |||
| WO9313066, | |||
| WO9314072, | |||
| WO9314762, | |||
| WO9318736, | |||
| WO9323548, | |||
| WO9325546, | |||
| WO9403476, | |||
| WO9405639, | |||
| WO9407858, | |||
| WO9413629, | |||
| WO9502684, | |||
| WO9512398, | |||
| WO9512572, | |||
| WO9524385, | |||
| WO9526337, | |||
| WO9534303, | |||
| WO9535308, | |||
| WO9535367, | |||
| WO9603318, | |||
| WO9606097, | |||
| WO9611943, | |||
| WO9615101, | |||
| WO9617816, | |||
| WO9633184, | |||
| WO9633187, | |||
| WO9636630, | |||
| WO9641609, | |||
| WO9731898, | |||
| WO9736869, | |||
| WO9813343, | |||
| WO9820891, | |||
| WO9820892, | |||
| WO9820893, | |||
| WO9822432, | |||
| WO9824805, | |||
| ZA9207782, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Jun 03 1998 | GPI NIL Holding, Inc. | (assignment on the face of the patent) | / | |||
| Jul 06 1998 | STEINER, JOSEPH P | GUILFORD PHARMACEUTICALS INC | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 009346 | /0627 | |
| Jul 06 1998 | HAMILTON, GREGORY S | GUILFORD PHARMACEUTICALS INC | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 009346 | /0627 | |
| Jul 07 1998 | GUILFORD PHARMACEUTICALS INC | GPI NIL Holdings, Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 009355 | /0621 | |
| Apr 05 2007 | GPI IP, LLC, D B A MGL PHARMA | GLIAMED, INC | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 019477 | /0568 |
| Date | Maintenance Fee Events |
| Jul 09 2004 | M1551: Payment of Maintenance Fee, 4th Year, Large Entity. |
| Jul 21 2008 | REM: Maintenance Fee Reminder Mailed. |
| Jan 09 2009 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
| Date | Maintenance Schedule |
| Jan 09 2004 | 4 years fee payment window open |
| Jul 09 2004 | 6 months grace period start (w surcharge) |
| Jan 09 2005 | patent expiry (for year 4) |
| Jan 09 2007 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Jan 09 2008 | 8 years fee payment window open |
| Jul 09 2008 | 6 months grace period start (w surcharge) |
| Jan 09 2009 | patent expiry (for year 8) |
| Jan 09 2011 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Jan 09 2012 | 12 years fee payment window open |
| Jul 09 2012 | 6 months grace period start (w surcharge) |
| Jan 09 2013 | patent expiry (for year 12) |
| Jan 09 2015 | 2 years to revive unintentionally abandoned end. (for year 12) |